Andere talen LianBio

Aandelen

Vertraagde tijd OTC Markets Andere beurzen 18:13:47 06-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,3168 ^USD	+3,87%		-2,46%	-92,91%

13/02	LianBio kondigt afronding van strategische evaluatie aan	CI
2023	Nanobiotix-partner draagt Aziatische commercialisatierechten voor oncologische therapie over aan Johnson & Johnson-eenheid	MT

LianBio(OTCPK:LIAN.Y) dropped from NASDAQ Composite Index	18/03
ADRs End Lower; Akso Health Group Declines 23%	15/03
LianBio Announces Voluntarily Delisting from Nasdaq	28/02
LianBio to Start Winding Down Operations; Complete Dissolution Expected in 2027	13/02
LianBio Announces Completion of Strategic Review	13/02
LianBio Announces Completion of Strategic Review	13/02
Nanobiotix : transfert de droits sur NBTXR3 en Asie	27/12
Nanobiotix Partner Transfers Asian Commercialization Rights for Oncology Therapy to Johnson & Johnson Unit	27/12
Sector Update: Health Care Stocks Mixed Premarket Tuesday	26/12
LianBio Assigns Rights to Nanobiotix's Oncology Therapy in China, Other Asian Markets to Janssen Pharmaceutica	26/12
LianBio Enters into Agreement Assigning its Rights for NBTXR3 in China and Other Asian Markets	26/12
LianBio Enters into Agreement with Janssen Pharmaceutica to Assign its Rights for NBTXR3 in China and Other Asian Markets	26/12
LianBio Finance Chief Resigns, Names Interim CFO	20/12
Asian Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading	20/12
LianBio Announces Departure of Chief Financial Officer	20/12
LianBio Announces Chief Financial Officer Changes	20/12
LianBio CEO Yizhe Wang Resigns; Board Member Adam Stone Named in Interim	19/12
Lianbio Announces Resignation of Yizhe Wang as Member of the Board of Directors	19/12
LianBio Announces Departure of Chief Executive Officer	19/12
Lianbio Announces Chief Executive Officer Changes	19/12

Geen resultaten voor deze zoekopdracht